"This expansion nearly doubles the size of our current facility putting us in a much better position to meet the growing demand for our research and cGMP manufacturing services," said Henry Hebel, COO. While at the conference, Mr. Hebel will present a talk entitled Developing a Successful Contract Manufacturing Organization Partnership: A Case Study where he will discuss what to expect from a CMO and present examples of challenging projects successfully completed by VGXI.
The Company also announced the addition of DNA vaccine pioneer, Dr. David Weiner, Ph.D., to VGXI's Scientific Advisory Board. Dr. Weiner currently serves as the Chairman of Inovio Biomedical's Scientific Advisory Board and as a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania.
VGXI also announced the addition of Sandra Jones as Director of Validation and David Colvin as Key Account Manager. Ms. Jones comes to VGXI from Beckman-Coulter, Inc. where she was the Quality Assurance Engineering Supervisor and Calibration Manager. She has 17 years of experience in FDA regulated industries, including food, pharmaceutical and medical devices. She holds a BS in Chemical Engineering from Prairie View A&M University and an Executive Management Certification in Finance & Accounting from Cornell University.
Mr. Colvin joins VGXI from Merck & Co., where he was responsible for selling cardiovascular and diabetic medications to cardiologists, endocrinologists and primary care physicians. Prior to joining Merck in 2006, he was the co-founder of SYNTHEGEN, LLC, a biotechnology company that marketed reagents for genomics research. He holds a BS in Biochemistry from Texas A&M University and an Executive Certification in Finance & Accounting from Rice University.
About VGXI, Inc.
VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. The Company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for client companies' clinical studies in the US and Europe, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI's ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. This rapid turnaround program provides consistent materials to build a reliable pre-clinical dataset.
VGXI, Inc., a leading provider of DNA plasmid manufacturing and development services, announced today at the 2010 DNA Vaccines Conference the expansion of its state-of-the-art cGMP plasmid manufacturing facility in The Woodlands, TX.
"This expansion nearly doubles the size of our current facility putting us in a much better position to meet the growing demand for our research and cGMP manufacturing services," said Henry Hebel, COO. 
